Trade Hikma Pharmaceuticals PLC - HIK CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.42 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023256% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001338% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | GBP | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||||||
| Commission on trade | 0% |
| Prev. Close | 19.42 |
| Open | 19.58 |
| 1-Year Change | 1.93% |
| Day's Range | 19.13 - 19.67 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 31, 2025 | 19.42 | -0.02 | -0.10% | 19.44 | 19.48 | 18.96 |
| Mar 28, 2025 | 19.29 | -0.58 | -2.92% | 19.87 | 19.97 | 19.29 |
| Mar 27, 2025 | 19.85 | -0.16 | -0.80% | 20.01 | 20.07 | 19.73 |
| Mar 26, 2025 | 20.13 | 0.25 | 1.26% | 19.88 | 20.23 | 19.85 |
| Mar 25, 2025 | 20.07 | 0.44 | 2.24% | 19.63 | 20.29 | 19.63 |
| Mar 24, 2025 | 19.84 | -0.19 | -0.95% | 20.03 | 20.19 | 19.75 |
| Mar 21, 2025 | 20.15 | 0.04 | 0.20% | 20.11 | 20.23 | 19.74 |
| Mar 20, 2025 | 20.09 | -0.16 | -0.79% | 20.25 | 20.43 | 19.73 |
| Mar 19, 2025 | 20.67 | 0.34 | 1.67% | 20.33 | 20.85 | 20.33 |
| Mar 18, 2025 | 20.47 | 0.36 | 1.79% | 20.11 | 20.55 | 20.09 |
| Mar 17, 2025 | 20.23 | -0.08 | -0.39% | 20.31 | 20.33 | 19.79 |
| Mar 14, 2025 | 20.07 | 0.00 | 0.00% | 20.07 | 20.21 | 19.90 |
| Mar 13, 2025 | 20.17 | -0.34 | -1.66% | 20.51 | 20.59 | 20.03 |
| Mar 12, 2025 | 20.63 | -0.20 | -0.96% | 20.83 | 20.99 | 20.53 |
| Mar 11, 2025 | 21.01 | 0.00 | 0.00% | 21.01 | 21.31 | 20.87 |
| Mar 10, 2025 | 20.99 | -0.40 | -1.87% | 21.39 | 21.57 | 20.99 |
| Mar 7, 2025 | 21.21 | -0.30 | -1.39% | 21.51 | 21.55 | 21.05 |
| Mar 6, 2025 | 21.49 | 0.14 | 0.66% | 21.35 | 21.79 | 21.23 |
| Mar 5, 2025 | 21.45 | -0.16 | -0.74% | 21.61 | 21.61 | 21.27 |
| Mar 4, 2025 | 21.17 | -0.56 | -2.58% | 21.73 | 21.73 | 21.17 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Hikma Company profile
Discover the latest Hikma share price today with our comprehensive live chart.
Hikma Pharmaceuticals plc. (HIK) creates and sells generic pharmaceutical solutions and products in the USA, North Africa, Europe, and the Middle East; with its headquarters located in London, UK. The company has operations in more than 50 countries and divides its work into three business units: Branded, Injectables, and Generics.
Hikma owns 29 manufacturing plants in 11 countries: Jordan, Saudi Arabia, Algeria, Egypt, Morocco, Tunisia, Sudan, United States, Portugal, Italy and Germany. The Hikma’s branded division offers 499 products in 1,256 dosage strength. The most popular products are: Amoclan, Omnisef, Blopress and Suprax. The injectables division vendors 200 products in 379 dosage forms.
Hikma pharmaceuticals share price is set and traded on the London Stock Exchange (LSE) under the ticker symbol HIK. The company constitutes the FTSE 100 and FTSE 350 Indices.
Hikma made an initial public offering on 11 November 2005, and Hikma pharmaceuticals shares were listed for the first time, raising gross proceeds of $124 million.
Hikma Pharmaceuticals was founded in Amman, Jordan, by Samih Darwazah in 1978. In August 1996, it became the first Arab company to export pharmaceutical products to the US.
The company’s biggest acquisitions include Jazeera Pharmaceutical, Saudi Arabia; Instituto Biochimico Pavese Pharma, Italy; Baxter International, US; Ribosepharm, Germany; Promopharm, Morocco, and Alkan Pharma, Egypt. All of these strategic acquisitions helped Hikma to establish itself as the world’s leading provider in its industry.
In May 2014, Hikma Pharmaceuticals plc significantly increased its presence in the injected medicine market by purchasing assets from the US generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million.
The most recent company acquisition was Roxane Laboratories in Columbus, US. It has majorly improved Hikma's position in a non-injectables business in the US market.
Hikma has been recognised as the Company of the Year by the Global Generics and Biosimilars Awards for four years in a row: from 2014 to 2017.
According to Hikma’s latest earnings report, the company delivered strong growth in revenue and profit in 2019 with a group core revenue of $2,203 million (up 6 per cent) and operating profit of $508 million (up 10 per cent).
Follow the Hikma share price today with Capital.com to spot the best trading opportunities. Track all the ups and downs of the HIK stock price and stay on top of the latest price fluctuations with our live Hikma stock chart.
| Industry: | Pharmaceuticals (NEC) |
1 New Burlington Place
LONDON
W1S 2HR
GB
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com